cilengitide has been researched along with erlotinib hydrochloride in 1 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | cilengitide (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, J; Kim, J | 1 |
1 other study(ies) available for cilengitide and erlotinib hydrochloride
| Article | Year |
|---|---|
Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Snake Venoms; Transforming Growth Factor beta1 | 2022 |